China still has ‘catching up to do’ to become biotech powerhouse, JPMorgan says
A lag in foundational research and looming geopolitical risks will weigh on China’s bid to build a world-class biotechnology innovation ecosystem, even as the sector’s overseas momentum remains strong, according to JPMorgan. “In China, there is still some catching up to do in basic research, particularly in biological and pharmaceutical research,” said Yang Huang, head of China healthcare research at…
Continue reading this story on South China Morning Post, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.